ID: ALA3408058

Max Phase: Preclinical

Molecular Formula: C20H11F3N4O2

Molecular Weight: 396.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  C#Cc1c[nH]nc1-c1nc(-c2ccc(Oc3ccc(C(F)(F)F)cc3)cc2)no1

Standard InChI:  InChI=1S/C20H11F3N4O2/c1-2-12-11-24-26-17(12)19-25-18(27-29-19)13-3-7-15(8-4-13)28-16-9-5-14(6-10-16)20(21,22)23/h1,3-11H,(H,24,26)

Standard InChI Key:  SBTQXERVMIRAMA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.33

Molecular Weight (Monoisotopic): 396.0834

AlogP: 4.92

#Rotatable Bonds: 4

Polar Surface Area: 76.83

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.11

CX Basic pKa:

CX LogP: 5.40

CX LogD: 5.40

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.50

Np Likeness Score: -1.64

References

1. Spink E, Ding D, Peng Z, Boudreau MA, Leemans E, Lastochkin E, Song W, Lichtenwalter K, O'Daniel PI, Testero SA, Pi H, Schroeder VA, Wolter WR, Antunes NT, Suckow MA, Vakulenko S, Chang M, Mobashery S..  (2015)  Structure-activity relationship for the oxadiazole class of antibiotics.,  58  (3): [PMID:25590813] [10.1021/jm501661f]

2. Leemans E, Mahasenan KV, Kumarasiri M, Spink E, Ding D, O'Daniel PI, Boudreau MA, Lastochkin E, Testero SA, Yamaguchi T, Lee M, Hesek D, Fisher JF, Chang M, Mobashery S..  (2016)  Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials.,  26  (3): [PMID:26733473] [10.1016/j.bmcl.2015.12.041]

Source

Source(1):

• Scientific Literature